Медикаментозное лечение пациентов с акромегалией, частично резистентных к терапии аналогами соматостатина


Анциферов М.Б., Пронин В.С., Алексеева Т.М.

Эндокринологический диспансер Департамента здравоохранения города Москвы. ГОУ ВПО “Первый МГМУ им. И.М. Сеченова” Минздравсоцразвития РФ, Москва.
Статья акцентирует внимание на проблеме лечения пациентов с активной формой акромегалии, частично резистентных к терапии аналогами соматостатина (АС). Приведен обзор клинических исследований, касающихся медикаментозного лечения акромегалии с использованием препаратов октреотида и ланреотида, обсуждены аспекты эффективности данных аналогов. Анализируется эффективность увеличения доз АС и комбинированного лечения агонистами дофамина и АС при лечении пациентов указанной группы. Предложены дифференцированные варианты лечебной тактики в отсутствие контроля заболевания на фоне монотерапии АС.

Литература


1. Reilchlin S. Etiology of acromegaly from the neuroendocrine point of view: a historical perspective. In Acromegaly: A Century of Scientific and Clinical Progress. Eds RJ Robbins & S Melmed. Plenum Press, New York, NY, USA. 1987:7–15.


2. Freda PU. Acromegaly. Aims of treatment. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009:102.


3. Clemmons DR, et al. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm. J Clin Endocrinol Metab 2003;88:4759–67.


4. Beckers A, Daly A. The epidemiology of acromegaly. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009:16.


5. Holdway IM, Rajasoora RC, Gamble GD. Factors influencing mortality in acromegaly. J Clin Endocrinol Metab 2004;89:667–74.


6. Swearingen B, et al. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. J Clin Endocrinol Metab 1998;83:3419–26.


7. Bates PR, Carson MN, Trainer PJ, et al. Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol 2008;68:136–42.


8. Bates AS, Van’t Hoff W, et al. An oudit of outcome of teratment in acromegaly. Q J Med 1993;86:293–99.


9. Murray RD, et al. Critical Analisysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly. J Clin Endocrinol Metab 2008;93:2957–68.


10. Freda PU, Katznelson L, van der Lely AJ, et al. Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analisis. J Clin Endocrinol Metab 2005;90:4465–73.


11. Neggers S, Lamberts S, van der Lely AJ. Acromegaly. Long-term treatment. In: Acromegaly. A handbook of history, current therapy and future prospects, 2009:183.


12. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Springer, Pituitary. DOI 10.1007/s 11102-0100282-z. Published online: 2010.


13. van der Lely AJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001;358:1754–59.


14. Neggers SJ, van Aken MO, Janssen JA, et al. Longterm efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly. J Clin Endocrinol Metab 2007;92:4598–601.


15. Sandret L, Maison P, Chanson P. Place of Cabergoline in Acromegaly: A meta-Analisis. J Clin Endocrinol Metab 2011;96(5):1327–35.


16. Colao A, et al. Beneficial effect of dose escalation of Octreotid-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157:579–87.


17. Giustina A, Bonadonna S, Bugari G, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial. Eur J Endocrinol 2009;161:331–38.


18. Auk J, Seppard MC. Does acromegaly enhance mortality? Rev Endocr Metab Disord 2008;9:33–39.


19. Wuster C, Both S, et al. Primary treatment of acromegaly with high-dose lanreotide: a case series. J Med Case Reports 2010;4:85.


20. Attanisio R, Lanzi R, et al. Effects of lanreotide Autogel on growth hormone, insulilike growth factor 1, and tumor size in acromegaly: a 1 – year prospective multicenter study. Endocrinol Pract 2008;14:846–55.


21. Toledano Y, Rot L, Greenman Y, et al. Efficacy of long-term lanreotide teratment in patients with acromegaly. Pituitary 2009;12:285–93.


22. Feenstra J, de Herder WW, et al. Combined therapy with somatostatin analogues and weekly pegvisomant in acromegaly. J Clin Endocrinol Metab 2005;92:4598–601.


23. Neggers SJCM , et al. Qualyty of life in Acromegalic Patients during Long-term Somatostatin Analog Treatment with and without pegvisomant. J Clin Endocrinol Metab 2008;93:3853–59.


24. Abs R, et al. Carbegoline in the Treatment of the Acromegaly: A Study in 64 patients. J Clin Endocrinol Metab 1998;83:374–78.


25. Cozzi R, et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin. Endocrinol 2004;61:209–15.


26. Selvarajah D, Webster J, Ross R, et al J. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005;152:569–74.


27. Sandret L, Maison P, Chanson P. Place of Cabergoline in Acromegaly: A meta-Analisis. J Clin Endocr Metabolosm 2011;96(5):1327–35.


28. Comparative therapeutic efficacy of Autogel, the new somatostatin analogue of lanreotide’s prolonged release form, in acromegalic patients responders to somatostatin. Final version: 09 November 2004.


29. Cendors JM, et al. Pharmacokinetics and population pharmacodinamic analisis of lanreotide Autogel. Metab Clin Experim 2005;54:1276–81.


30. Attanisio R, et al. Effects of lanreotide autogel on growth hormone, insulinlike growth factor 1n and tumor size in acromegaly: A 1-year prospective multicenter study. Endocr Practice 2008; 14:846–55.


Похожие статьи


Бионика Медиа